MarketCap
Facebook
X
Telegram
Harrow Health Financial Ratios 2025-1998 | HROW
Brief overview of Harrow Health's valuation multiples
The review covers five available annual periods spanning 2021 to 2025.
Key multiples at the end of the period are EV/EBITDA 69.39x (median 161.83x), P/S 7.1x (median 5.41x), P/B 37.13x (median 18.87x). On average, multiples differ from their five-year medians by only -1.6%. Valuation is near its familiar historical range.
End-period return metrics are ROE -9.8%, ROA -1.3%, ROCE 58.2%. Current return ratios are negative, materially weakening the fundamental profile.
PEG of 0.51x shows valuation is not outpacing embedded growth. The conclusion depends on earnings durability.
A shorter cycle, from -28.6 days to -46.2 days, indicates faster release of cash from operations.
Overall picture
Harrow Health's multiples form a balanced picture without a clear discount or premium. Future appeal depends on earnings and return trends.
Annual Financial Ratios Harrow Health
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
P/E |
-376.4 | -107.3 | -14.2 | -34.0 | -11.5 | -69.4 | 969.2 | 9.0 | -3.2 | -1.6 | -3.6 | -6.7 | -9.3 | -6.9 | -1.5 | -251.8 | - | - | - | - | - | - | - | - | - | - | - | - |
P/S |
7.1 | 9.4 | 2.7 | 5.4 | 2.8 | 4.8 | 3.2 | 3.2 | 1.4 | 1.5 | 5.9 | 40.5 | 7098.6 | 370.7 | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
EPS |
-0.1 | -0.5 | -0.8 | -0.5 | -0.7 | -0.1 | 0.0 | 0.7 | -0.6 | -1.5 | -1.7 | -1.1 | -0.9 | -1.2 | -2.6 | -0.2 | - | - | - | - | - | - | - | - | - | - | - | - |
EV (Enterprise Value) |
2.21 B | 2.15 B | 515 M | 513 M | 252 M | 260 M | 190 M | 149 M | 55.5 M | 42 M | 69.9 M | 61.2 M | 56.1 M | 27.7 M | 3.15 M | 638 M | -1.59 M | - | - | - | - | - | - | - | - | - | - | - |
EBITDA per Share |
0.87 | 0.28 | 0.05 | 0.12 | 0.12 | 0.135 | 0.075 | -0.154 | -0.519 | -1.11 | -1.48 | -1.1 | -0.887 | -0.929 | -2.36 | -0.16 | - | - | - | - | - | - | - | - | - | - | - | - |
EV/EBITDA |
69.4 | 212.9 | 346.6 | 161.8 | 72.8 | 70.2 | 90.6 | -41.3 | -4.7 | -2.3 | -4.4 | -5.9 | -7.2 | -6.5 | -1.7 | -255.2 | - | - | - | - | - | - | - | - | - | - | - | - |
PEG |
-3.13 | -1.14 | 0.51 | 1.13 | 0.28 | 0.03 | -9.79 | -0.04 | 0.05 | 0.16 | -0.07 | -0.25 | 0.32 | 0.12 | 0.03 | - | - | - | - | - | - | - | - | - | - | - | - | - |
P/B |
37.1 | 27.1 | 4.9 | 17.6 | 18.9 | 8.7 | 5.9 | 5.3 | 14.7 | 4.7 | -41.2 | 8.3 | 4.7 | 3.7 | -0.8 | -613.8 | - | - | - | - | - | - | - | - | - | - | - | - |
P/CF |
44.1 | -84.5 | 90.5 | 281.2 | 40.6 | -111.3 | -183.6 | -86.7 | -3.9 | -1.6 | -4.6 | -9.3 | -15.9 | -19.3 | -4.9 | -277.3 | - | - | - | - | - | - | - | - | - | - | - | - |
ROE % |
-9.80 | -25.10 | -34.50 | -51.05 | -159.55 | -12.51 | 0.61 | 59.09 | -458.32 | -296.75 | 1147.94 | -124.15 | -50.58 | -53.85 | 56.11 | 243.80 | -788.90 | -72.28 | -122.75 | 143.90 | 197.83 | 311.51 | 377.23 | 478.15 | 1068.16 | 1921.13 | 5100.00 | - |
ROA % |
-1.29 | -4.49 | -7.82 | -8.95 | -18.31 | -5.84 | 0.28 | 29.57 | -50.11 | -70.05 | -112.51 | -98.79 | -48.49 | -50.29 | -592.67 | -718.50 | - | - | - | - | - | - | - | - | - | - | - | - |
ROCE % |
58.18 | 12.67 | 0.61 | 6.95 | 14.30 | 1.60 | -1.63 | -13.89 | -67.04 | -89.83 | -169.26 | -116.87 | -50.87 | -41.80 | 55.25 | 241.04 | - | - | - | - | - | - | - | - | - | - | - | - |
Current Ratio |
1.1 | 1.2 | 1.3 | 1.2 | 1.1 | 3.7 | 3.0 | 2.8 | 1.5 | 1.5 | 1.1 | 5.8 | 24.2 | 15.1 | 0.1 | 0.3 | - | - | - | - | - | - | - | - | - | - | - | - |
DSO |
87.8 | 32.4 | 22.5 | 1.7 | 0.3 | 19.9 | 19.5 | 17.3 | 22.1 | 53.5 | 31.6 | 17.9 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
DIO |
65.1 | 79.9 | 80.1 | 77.3 | 82.0 | 100.0 | 71.9 | 40.5 | 60.8 | 68.4 | 99.0 | 124.5 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
DPO |
199.1 | 234.7 | 176.6 | 144.6 | 110.9 | 99.2 | 161.5 | 138.1 | 105 | 131.4 | 238.9 | 262.7 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Cycle |
152.9 | 112.3 | 102.6 | 79.0 | 82.3 | 119.9 | 91.4 | 57.8 | 82.9 | 121.8 | 130.6 | 142.4 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cash Conversion Cycle |
-46.2 | -122.5 | -74.0 | -65.5 | -28.6 | 20.6 | -70.0 | -80.2 | -22.1 | -9.5 | -108.3 | -120.4 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Quarterly Financial Ratios Harrow Health
| 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
EPS |
-0.74 | 0.03 | 0.14 | -0.5 | - | -0.12 | -0.18 | -0.38 | - | -0.13 | -0.14 | -0.22 | - | -0.24 | -0.23 | -0.09 | - | -0.31 | -0.11 | 0.01 | - | 0.33 | -0.01 | -0.5 | - | -0.45 | -0.09 | 0.46 | - | -0.12 | 0.12 | -0.17 | - | -0.28 | 0.07 | -0.26 | - | -0.29 | -0.35 | -0.43 | - | -0.41 | -0.39 | -0.33 | - | -0.27 | -0.28 | -0.26 | - | -0.23 | -0.25 | -0.19 | - | -0.2 | -0.39 | -1.3 | - | -0.04 | -0.08 | -0.22 |
EBITDA per Share |
-0.58 | 0.41 | 0.32 | -0.3 | - | 0.05 | 0.05 | -0.19 | - | 0.06 | 0.08 | 0.05 | - | - | 0.08 | 0.09 | - | -0.09 | 0.19 | 0.13 | - | 0.08 | -0.11 | -0.01 | - | -0.16 | -0.01 | -0.01 | - | 0.03 | 0.01 | -0.07 | - | -0.08 | -0.12 | -0.21 | - | -0.29 | -0.27 | -0.35 | - | -0.35 | -0.36 | -0.33 | - | -0.27 | -0.28 | -0.26 | - | -0.23 | -0.25 | -0.19 | - | -0.2 | -0.29 | -0.33 | - | -0.03 | -0.07 | -0.21 |
ROE % |
-115.42 | -26.59 | -39.89 | -72.48 | -40.98 | -46.80 | -58.66 | -78.39 | -55.86 | -805.74 | -915.58 | -921.45 | -890.59 | -941.89 | -202.85 | -86.41 | -61.37 | -29.59 | 20.84 | -15.80 | -16.58 | -57.96 | -98.32 | -56.46 | -8.98 | -19.14 | 32.44 | 26.83 | -14.16 | -231.83 | -164.92 | -366.55 | -352.35 | -412.21 | -266.67 | -393.32 | -201.88 | 83.46 | 412.63 | 708.08 | 777.98 | 747.89 | 430.70 | 132.86 | -90.47 | -104.21 | -88.81 | -66.65 | -38.13 | -50.59 | -49.90 | -49.02 | -39.32 | -34.30 | -12.16 | 26.33 | 40.13 | 5.02 | 9.67 | 25.43 |
ROA % |
-9.73 | -4.35 | -6.75 | -12.78 | -7.90 | -9.44 | -10.12 | -11.07 | -6.48 | -13.01 | -17.83 | -18.44 | -15.39 | -23.49 | -19.28 | -12.53 | -10.03 | 5.00 | 12.69 | -7.45 | -7.84 | -27.25 | -46.31 | -26.67 | -4.21 | -9.30 | 15.21 | 12.14 | -7.09 | -30.89 | -19.60 | -45.63 | -38.52 | -52.65 | -45.88 | -68.59 | -47.66 | -75.62 | -87.89 | -92.75 | -76.25 | -100.19 | -97.57 | -93.88 | -71.99 | -85.17 | -75.30 | -59.25 | -36.55 | -48.19 | -47.20 | -46.01 | -36.71 | -89.77 | -180.31 | -436.71 | -423.83 | -53.06 | -102.18 | -268.59 |
ROCE % |
-42.47 | 36.74 | 8.00 | -26.48 | -6.58 | -4.27 | 4.10 | 7.09 | 18.60 | 7.69 | 36.71 | 47.63 | 42.01 | 19.11 | 48.26 | 27.40 | 5.82 | 11.69 | 22.78 | 2.22 | -8.24 | -24.12 | -32.76 | -22.96 | -20.65 | -23.27 | -9.92 | -14.35 | -12.34 | -118.04 | -230.79 | -390.06 | -382.87 | -454.57 | -411.19 | -354.18 | -192.38 | 62.42 | 385.46 | 672.83 | 731.19 | 701.02 | 414.28 | 134.29 | -90.76 | -104.59 | -89.18 | -66.99 | -38.34 | -50.84 | -48.20 | -36.96 | -27.21 | -23.30 | -2.22 | 33.31 | 36.83 | 3.91 | 8.57 | 24.34 |
Current Ratio |
1.1 | 1.1 | 1.2 | 1.2 | 1.2 | 1.2 | 1.2 | 1.3 | 1.3 | 1.4 | 1.1 | 1.1 | 1.2 | 1.0 | 1.1 | 1.1 | 1.1 | 1.2 | 1.3 | 2.0 | 1.9 | 1.9 | 1.9 | 1.9 | 1.9 | 1.9 | 1.9 | 1.9 | 2.0 | 2.0 | 2.0 | 2.0 | 1.1 | 1.1 | 1.1 | 1.1 | 1.3 | 1.3 | 1.3 | 1.3 | 0.9 | 0.9 | 0.9 | 0.9 | 4.9 | 4.9 | 4.9 | 4.9 | 24.2 | 24.2 | 24.2 | - | - | - | - | - | 0.1 | 0.1 | 0.1 | - |
DSO |
184.6 | 99.6 | 111.6 | 184.5 | - | 98.6 | 76.2 | 86.0 | - | 48.9 | 41.4 | 32.1 | - | 27.0 | 24.9 | 21.6 | - | 19.2 | 17.5 | 9.9 | - | 16.9 | 30.1 | 10.6 | - | 14.4 | 13.6 | 8.5 | - | 16.3 | 16.8 | 11.3 | - | 21.5 | 20.4 | 14.6 | - | 5.2 | 4.3 | 3.8 | - | 6.1 | 8.3 | 5.4 | - | 0.8 | 0.6 | 91.2 | - | - | - | - | - | - | - | - | - | - | - | - |
DIO |
78.0 | 62.8 | 62.6 | 63.0 | - | 74.3 | 73.6 | 93.7 | - | 79.2 | 80.5 | 86.2 | - | 70.7 | 66.5 | 65.9 | - | 72.2 | 86.8 | 102.4 | - | 97.8 | 112.8 | 91.4 | - | 74.2 | 57.6 | 60.1 | - | 39.9 | 40.3 | 45.8 | - | 60.3 | 62.4 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
DPO |
120.0 | 109.2 | 170.1 | 222.9 | - | 201.1 | 155.8 | 195.1 | - | 161.3 | 165.0 | 164.6 | - | 158.3 | 111.4 | 100.2 | - | 115.7 | 115.5 | 129.6 | - | 116.8 | 134.8 | 166.5 | - | 191.0 | 148.5 | 182.0 | - | 153.5 | 154.8 | 131.5 | - | 125.6 | 130.0 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Cycle |
- | 162.4 | 174.2 | 247.5 | - | 172.9 | 149.8 | 179.8 | - | 128.1 | 121.9 | 118.3 | - | 97.7 | 91.5 | 87.5 | - | 91.4 | 104.3 | 112.3 | - | 114.7 | 143.0 | 102.0 | - | 88.5 | 71.2 | 68.6 | - | 56.2 | 57.1 | 57.0 | - | 81.8 | 82.8 | 14.6 | - | 5.2 | 4.3 | 3.8 | - | 6.1 | 8.3 | 5.4 | - | 0.8 | 0.6 | 91.2 | - | - | - | - | - | - | - | - | - | - | - | - |
Cash Conversion Cycle |
- | 53.2 | 4.1 | 24.5 | - | -28.1 | -6.0 | -15.4 | - | -33.1 | -43.1 | -46.3 | - | -60.6 | -20.0 | -12.7 | - | -24.3 | -11.2 | -17.3 | - | -2.1 | 8.2 | -64.6 | - | -102.5 | -77.3 | -113.5 | - | -97.3 | -97.7 | -74.5 | - | -43.8 | -47.2 | 14.6 | - | 5.2 | 4.3 | 3.8 | - | 6.1 | 8.3 | 5.4 | - | 0.8 | 0.6 | 91.2 | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Multiples are an important financial analysis tool for the company Harrow Health, allowing investors and analysts to quickly assess the company’s value and investment attractiveness based on the ratio of market indicators to the company’s financial performance. Essentially, multiples express how the market values the company relative to its earnings, revenue, equity, or other key metrics.
Advantages of Using Financial Ratios- Simplified Data Analysis
Financial ratios transform large volumes of accounting data into compact and easily interpretable indicators, significantly simplifying the assessment of the company’s condition. - Comparability Between Companies
Multiples standardize financial metrics, enabling objective comparison of companies of different sizes, industries, and market capitalizations. - Identification of Trends and Issues
Regular analysis of ratios helps track the dynamics of financial health, identify strengths and weaknesses of the business, as well as potential risks. - Decision Support
Financial multiples serve as an important tool for investors, creditors, and company management in making investment, credit, and managerial decisions. - Accelerated Assessment of Investment Attractiveness
Ratios allow quick determination of key performance, liquidity, and financial stability indicators, facilitating prompt evaluation of companies’ attractiveness for investments.
Using multiples enables comparison between companies, even if they differ in size or industry, as they standardize financial data into ratios convenient for analysis. This is especially useful for evaluating companies where direct analysis of financial statements may be complex or require in-depth knowledge.
USA
Irlanda
Canada
Schweden
France
China
